Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jiedu Tongluo granules (JDTLG) is a patented traditional Chinese medicine (TCM) formulation developed by the Xiyuan Hospital of China Academy of Chinese Medical Sciences for the treatment of post-stroke depression (PSD). It is specifically indicated for PSD patients with qi deficiency and blood stasis syndrome. The formulation is a complex herbal preparation containing key active compounds such as Ginsenoside Rg1, Ginsenoside Re, Ginsenoside Rb1, and Baicalin. Research indicates that JDTLG exerts antidepressant and neuroprotective effects, potentially through the regulation of the NMDAR/BDNF signaling pathway. It has been studied in randomized, double-blind, placebo-controlled pilot clinical trials to evaluate its safety and therapeutic efficacy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jiedu Tongluo granules.